Engflag

Verorab

Quick links to important sections

Verorab

Verorab_ES

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Verorab

Property Description
Active Ingredient Rabies Virus (Inactivated)
Form Lyophilized powder and solvent for suspension for injection
Pharmacological Class Viral Vaccine; Active Immunizing Agent (ATC Code J07BG01)
Common Use Prophylaxis (Prevention) against Rabies in all age groups
Origin Produced on Vero Cell Line (Cell Culture Vaccine)

Verorab: An Overview of the Rabies Vaccine

Verorab is an Immunological Agent formally classified as a Purified Inactivated Rabies Vaccine (PVRV), designed to provide protection against the Rabies Virus. Manufactured by Sanofi Pasteur, this prescription-only (Rx) medicine functions as an Active Immunizing Agent, initiating the body’s own defense mechanisms against the virus. It has an established history of clinical use since 1985 and is indicated for prophylaxis in patients of all ages.

The product's classification as a vaccine signifies its general purpose: to establish immunity against a specific pathogen rather than to treat an active disease. It is included in the WHO List of Prequalified Vaccines.

Composition and Technical Origin

The active component in Verorab is the Inactivated Rabies Virus Antigen, derived from the WISTAR PM/WI 38 1503-3M strain, which is rendered harmless through rigorous chemical inactivation with agents like beta-propiolactone. The vaccine's distinguishing technical origin is its growth substrate, the Vero Cell Line, a continuous mammalian cell system utilized under strict controls. This technology contributes to the high purity that is characteristic of the PVRV type, distinguishing it from older vaccine types.

Verorab is supplied as a freeze-dried, lyophilized powder that is reconstituted with the supplied solvent, primarily a sodium chloride solution, to form a suspension immediately prior to its parenteral administration. This form ensures product stability and integrity.

General Purpose and Immunological Role

The primary purpose of Verorab is to establish active immunity and provide prophylaxis against the Rabies Virus. It works by presenting inactivated viral antigens, prompting the immune system to generate specific, protective neutralizing antibodies and immune memory cells.

The general benefit is the prevention of disease development, serving as a component for individuals at risk due to travel or occupation (pre-exposure prophylaxis, PrEP), as well as following suspected exposure (post-exposure prophylaxis, PEP). Its role is foundational in preventing the rabies virus from accessing the central nervous system, which is its essential function in preventative medicine.

Regulatory References

  1. WHO List of Prequalified Vaccines

What side effects are possible with Verorab?

Possible side effects and safety information

The safety profile of Verorab is officially documented by health authorities based on frequency, the physiological system affected, and specific risk populations.

Adverse Reaction Scope and Classification

Category Description based on Regulatory Sources
Frequency Classification Very Common (ge 1/10): Localized pain, redness, or swelling at the injection site, headache, malaise (feeling unwell), muscle pain (myalgia). In infants and toddlers, very common effects specifically include irritability, somnolence (drowsiness), and inconsolable crying. Common (ge 1/100 to < 1/10): Fever, chills, joint pain (arthralgia), nausea, vomiting, diarrhoea, abdominal pain, and Lymphadenopathy (swollen glands).
System-Organ Classes Adverse reactions are classified by the affected system, including General Disorders and Administration Site Conditions, Nervous System Disorders (e.g., headache, dizziness), Gastrointestinal Disorders, and Musculoskeletal and Connective Tissue Disorders [Source 1.2].
Serious Adverse Reactions Rare but significant events, reported in post-marketing surveillance, include anaphylactic reaction (a severe allergic event), convulsions, encephalopathy, and serum sickness-like reactions [Source 1.3].

Population-Specific Safety and Limitations

Safety notes are included in official documents for specific groups and situations:

  • Immunodeficiency: Individuals with decreased immunity (e.g., due to illness or immunosuppressive treatments) may have an inadequate immune response, and serological monitoring of antibody levels may be recommended [Source 1.2, 1.4].
  • Pregnancy and Lactation: Due to the severe nature of rabies, post-exposure vaccination is typically not contraindicated. Clinical use to date has not shown evidence of harmful effects on the fetus [Source 1.4].
  • Phenylketonuria (PKU): The vaccine contains phenylalanine and must be used with caution in individuals with PKU [Source 1.4].
  • Safety Restriction: The vaccine must not be administered via the intravascular route (must not penetrate a blood vessel) [Source 1.4]. Caution is also required for those with known allergies to trace amounts of polymyxin B, streptomycin, or neomycin [Source 1.4].

Time-Related Safety Patterns

Most reported adverse effects are generally mild and short-lived [Source 1.1]. However, delayed immune responses like serum sickness-like reactions may occur days or weeks after the vaccine is administered [Source 1.2].

The overall safety profile is structured by these classifications, indicating that while common, localized, and transient symptoms are the most frequent effects, official labeling clearly documents rare but serious systemic and neurological reactions, alongside specific warnings for at-risk populations.

Overdose and Emergency Response

The official regulatory documentation for Verorab establishes that no cases of overdose were reported in clinical trials, meaning a specific, dose-dependent toxicity syndrome is not defined in the product labeling.

If an excessive dose were to occur, regulatory sources indicate the primary risk is an increased likelihood and/or severity of known adverse events. This may manifest as more pronounced injection site reactions or heightened systemic reactions such as headache and fever. No specific antidote is known for this vaccine.

The most severe potential outcome that requires action is the risk of a life-threatening anaphylactic reaction (severe allergic reaction). Immediate medical attention is required for any sign of severe systemic reaction, including swelling of the face or throat, difficulty breathing, or passing out. In such scenarios, appropriate medical treatment must be immediately available, and emergency services must be contacted immediately.

Management for over-administration is restricted to symptomatic and supportive treatment. Hospital monitoring may be required for severe systemic effects, and observation may be needed to manage fainting (syncope) following administration. No specific overdose considerations are detailed for pediatric or geriatric populations.

Therapeutic Uses of Verorab

What Verorab Treats: Main Uses and Benefits

Supportive Management Following Suspected Exposure (Post-Exposure Prophylaxis)

This category addresses the medical requirement for intervention following confirmed or suspected exposure to the rabies virus, such as transdermal bites or contamination of broken skin. The vaccine is utilized in clinical settings following potential exposure to initiate an active immune response. The primary objective is to prompt the body's defenses to respond to the virus, aiding in the prevention of the severe symptoms associated with the progression of the condition.

Preventative Support for High-Risk Scenarios (Pre-Exposure Prophylaxis)

This application involves providing foundational protection for specific groups who face continuous or recurring risks of exposure. It is relevant for individuals in high-risk occupations or environments, including veterinarians, laboratory personnel, and adults and children traveling to endemic areas. The protection provided serves to establish a baseline immune readiness, assisting with maintaining biological stability in the event of future exposure.

Management of Severe Neurological Symptom Clusters

The vaccine is relevant for addressing the risk of symptom clusters that become intense or disruptive, specifically manifestations related to increased neurological or muscular activity caused by the virus. It is used as a measure to manage the potential for these manifestations. By establishing an immune response, the vaccine contributes to reducing the overall risk of the symptom load and assists with maintaining functional stability related to neurological health.

Quick Fact: Relief for Functional Stability Verorab supports the body in avoiding the development of symptoms linked to organ-specific functional stress.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Verorab — Official Regulatory Information

Category Official Regulatory Statement
Populations for whom use is allowed Indicated for pre-exposure and post-exposure prophylaxis against rabies in all age groups, including infants, children, and adults.
Populations for whom use is contraindicated Pre-Exposure Prophylaxis (PrEP): Contraindicated in individuals with a known systemic hypersensitivity reaction to the active substance or any excipients. Post-Exposure Prophylaxis (PEP): No contraindications exist, given the fatal outcome of declared rabies infection.
Age-related eligibility rules Dosage is identical for the paediatric and adult populations. Caution is required for very premature infants (le 28 weeks gestation) due to a labeled risk of apnoea and the need for respiratory monitoring.
Condition-specific eligibility rules Vaccination for PrEP must be postponed in the case of acute or febrile illness. The vaccine contains phenylalanine, which may be harmful to patients with Phenylketonuria (PKU).
Pregnancy and lactation eligibility status Pregnancy is not a contraindication for post-exposure prophylaxis. The vaccine can be used during breast-feeding.
Eligibility-related restrictions Immunodeficiency: The immune response may be inadequate, requiring serological monitoring after vaccination. Coagulation Disorders: Use with caution due to the risk of bleeding from intramuscular administration.

Connection to the Overall Eligibility Profile:

Regulatory documents establish that Verorab's eligibility is determined by the context of use: it is universally permitted following suspected rabies exposure but has limited contraindications for elective use (PrEP). The label confirms eligibility across all ages and for pregnant/lactating individuals, while imposing conditional use and warnings for populations with clotting disorders, immunodeficiency, or specific metabolic conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Verorab primarily through pharmacodynamic interference with the immune response and through specific administrative constraints.

Pharmacodynamic and Immunological Interference

Interacting Substance Category Documented Interaction Pattern Regulatory Consequence
Immunosuppressive Treatments (e.g., Corticosteroids, Ciclosporin, Chemotherapy) Interference with the production of protective antibodies against the vaccine antigen. Formal risk of vaccination failure, necessitating post-vaccination serological testing.
Rabies Immunoglobulins (RIGs) Interference with the development of the active immune response. Mandatory separation of injection site from the vaccine site.

Administrative and Procedural Constraints

The co-administration of Verorab is subject to strict regulatory constraints to prevent physical or immunological interference. The vaccine is prohibited from being mixed with any other medicinal product or other vaccine in the same syringe. The concomitant administration of Rabies Immunoglobulins (RIGs) is permitted only if injected at a different anatomical site from the vaccine to mitigate interference with the immune response.

Furthermore, while permitted for co-administration during the same visit, the Vi polysaccharide typhoid vaccine must also be injected at a separate site.

Mechanism of Action

How Verorab Works

Verorab is a purified, inactivated (non-live) rabies vaccine that operates by engaging the adaptive immune system, initiating a targeted immune-signaling cascade. This mechanism results in specific physiological adjustments within the immune system.

️ Activation of Antigen-Presenting Pathways

The mechanism begins with the introduction of the non-infectious viral antigen, the rabies glycoprotein, which is immediately recognized and processed by antigen-presenting cells (APCs). This process engages the initial molecular pathways of the adaptive immune system, serving as the necessary first step to prime the body's defense forces.

Induction of Humoral Immunity Cascade

This is the central pathway: the presented antigen stimulates T-cells, which in turn drive B-lymphocytes to differentiate into specialized plasma cells. These cells rapidly initiate the systemic production of rabies virus-neutralizing antibodies (RVNAs). This physiological effect involves the accumulation of RVNAs, which function by binding to the viral glycoprotein and hindering the interaction of the virus with host cells.

Establishment of Immunological Memory

A secondary mechanistic domain is the formation of long-lived memory B-cells and T-cells. This biological process establishes a population of memory cells that retain the recognition specificity for the antigen. This pathway is associated with the secondary (anamnestic) response characterized by rapid and enhanced production of immune components upon subsequent exposure or re-engagement.

Dosage and Administration Information

Verorab is an inactivated rabies vaccine administered as a suspension for injection after reconstitution of the lyophilized powder with its accompanying solvent. The vaccine is administered by a healthcare professional, as the preparation process requires specific steps, including reconstituting the powder and using a new sterile syringe and needle for administration to ensure proper technique and patient safety.

Administration Route and Site

Verorab can be administered via the intramuscular (IM) or intradermal (ID) route, based on the specific vaccination schedule and country guidelines. It must not be injected intravenously (into a blood vessel) or into the gluteal area (buttocks).

  • Intramuscular (IM) Use: A dose of 0.5 mL is typically given. For adults and older children, the preferred site is the deltoid muscle (upper arm). For infants and young children, the injection is given into the anterolateral area of the thigh muscle.
  • Intradermal (ID) Use: A smaller dose of 0.1 mL is administered at each injection site, preferably in the upper arm or forearm. This route is used for certain pre-exposure and post-exposure prophylaxis schedules as recommended for specific clinical protocols.

Dosage Schedules

Verorab is used for both Pre-Exposure Prophylaxis (PrEP) for at-risk individuals and Post-Exposure Prophylaxis (PEP) following potential rabies exposure. The number of doses and the specific schedule (such as 3-dose, 4-dose, or 5-dose regimens) are determined by the healthcare provider based on the patient's exposure category, immune status, and local official recommendations. For previously unvaccinated individuals requiring PEP, initial immediate and thorough wound cleansing is mandatory, and in severe exposure cases, Rabies Immunoglobulin (RIG) is administered alongside the first dose of the vaccine.

It is crucial to adhere strictly to the schedule determined by a healthcare provider to ensure effective protection.

Recent Clinical Evidence

Verorab: Recent Clinical Evidence

Recent clinical trials and reviews affirm the role of Verorab (Purified Vero Cell Rabies Vaccine, PVRV) in both Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) against rabies, aligning with global health recommendations.

Immunogenicity and Schedules

Studies consistently report high rates of seroconversion—the achievement of a protective level of rabies virus neutralizing antibodies (RVNA) of 0.5 IU/mL—following the recommended vaccination schedules.

  • Post-Exposure Prophylaxis (PEP): Research involving PEP regimens, including the intramuscular Essen schedule and various intradermal (ID) schedules, shows seroconversion rates 99% in healthy individuals by day 14 to day 28 of the regimen. Clinical trials have also evaluated non-inferiority of various simplified ID regimens compared to standard protocols.
  • Pre-Exposure Prophylaxis (PrEP): For PrEP, recent data support the immunogenicity of both the 3-dose (Days 0, 7, 21/28) and certain 2-dose (Days 0, 7) intramuscular schedules in generating adequate RVNA titers, particularly for short-term protection.

Safety and Persistence

Clinical studies indicate that the vaccine is generally well-tolerated, with safety profiles often comparable to other licensed rabies vaccines. Most reported adverse events are mild and transient, such as pain or tenderness at the injection site. Serious adverse events are rare.

Research has also examined antibody persistence following vaccination. While antibody levels naturally decline over time, long-term follow-up studies confirm that booster doses, when administered in accordance with risk category guidelines, effectively prompt a rapid and robust neutralizing antibody response.

How should Verorab be stored and disposed of?

The lyophilized powder and solvent for Verorab must be stored in a refrigerator, strictly maintained between 2 C and 8 C.

Storage Restriction Requirement as per Regulatory Labeling
Temperature Limit Do not freeze the vaccine, as freezing destroys the product.
Protection/Packaging Keep the product in its original outer package, protected from light.
Child Safety Store the vaccine out of the sight and reach of children.

After reconstitution, the stability window is limited. For intramuscular administration, the vaccine must be used immediately. If used for intradermal administration, physical-chemical stability is shown for up to 6 hours at leq 25 C and protected from light, after which the unused portion must be discarded. Disposal of unused, expired, or waste material must be done in accordance with local requirements, which typically involves returning the product to a pharmacy or disposal via incineration in a clinical setting.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Verorab found in:

A-Z Index: